Written by the Nuvirox Research Team
Short answer: mostly no, based on the best available evidence. A 2024 meta-analysis pooling 8 randomized trials found no significant benefit of NMN on cholesterol or glucose markers overall — though one small trial did find LDL and non-HDL cholesterol dropped meaningfully. The honest picture is "not proven," not "proven not to work."
Key Points
- A 2024 meta-analysis of 8 RCTs (342 adults) found NMN produced no significant change in fasting glucose, insulin, or lipid profile overall.
- One small 28-day trial of a crystalline NMN formulation found significant drops in LDL and non-HDL cholesterol, plus reduced body weight and diastolic BP.
- An 8-week safety trial of NR specifically found it did not raise LDL cholesterol — useful reassurance, but not evidence of a lipid-lowering effect either.
Why would a vitamin B3 derivative touch your cholesterol at all?
This isn't as far-fetched as it sounds. Niacin (vitamin B3, nicotinic acid) has been a prescription-strength cholesterol treatment for decades — at pharmacological doses far higher than what's in most supplements, and with side effects (flushing, liver enzyme changes) that limit its use. NAD+ precursors like NR and NMN are chemically related to niacin but metabolize differently, and in animal studies they've been linked to improved fatty-acid oxidation in the liver, partly through activating the enzyme SIRT1. That's the proposed pathway: more NAD+ availability → more SIRT1 activity → better lipid handling in the liver.
The open question is whether that pathway produces a measurable change in blood cholesterol in humans, at supplement doses, over a realistic timeframe.
The meta-analysis: the most rigorous answer we have
The most comprehensive answer comes from a 2024 systematic review and meta-analysis that pooled 8 randomized controlled trials of NMN, covering 342 middle-aged and older adults, with doses from 250–2,000 mg/day over 14 days to 12 weeks. The random-effects analysis found no statistically significant benefit of NMN on fasting glucose, fasting insulin, HbA1c, insulin resistance (HOMA-IR), or lipid profile across the pooled trials [1]. The authors were explicit that, based on the current small number of RCTs in mostly healthy adults, short-term NMN supplementation did not show significant positive effects on glucose control or lipid profile.
Study snapshot: 2024 meta-analysis of NMN and metabolic markers
| Design | Systematic review + random-effects meta-analysis |
| Trials pooled | 8 RCTs |
| Participants | 342 adults, mostly non-diabetic, 49% female |
| Dose range | 250–2,000 mg/day, 14 days–12 weeks |
| Key finding | No significant effect on lipid profile or glucose markers |
The counter-signal: one trial that did find a change
Set against that null result is a smaller but notable trial: a 28-day randomized study of MIB-626, a crystalline microcrystalline NMN formulation, given to 30 overweight or obese adults age 45+. That trial found MIB-626 significantly reduced total LDL and non-HDL cholesterol, alongside reductions in body weight and diastolic blood pressure, compared to placebo [2]. It's a real, randomized, controlled result — but it's a single small trial, in a specific population (overweight/obese), using a specific formulation, and the researchers themselves framed it as rationale for larger confirmatory trials rather than a settled finding.
The two results aren't necessarily contradictory — a pooled analysis of mostly healthy, non-obese adults finding no average effect is compatible with a targeted effect showing up specifically in overweight or metabolically stressed populations. But that's a hypothesis, not something the current evidence confirms.
What about people already managing high cholesterol?
None of the available trials enrolled people with diagnosed hyperlipidemia or on cholesterol-lowering medication such as statins. If your LDL is elevated enough to be a medical concern, this research doesn't tell you anything about how an NAD+ precursor would perform alongside or instead of established treatment — that's a conversation for your doctor, not a supplement label.
Frequently asked questions
Does NAD+ or NMN lower cholesterol?
The best current evidence (a meta-analysis of 8 RCTs) found no significant average effect on cholesterol. One smaller trial found a real LDL reduction in overweight adults — a promising but unconfirmed signal, not a proven effect.
Is nicotinamide riboside the same as niacin for cholesterol?
No. Niacin (nicotinic acid) is an established, higher-dose prescription cholesterol treatment with a different metabolic pathway and known side effects. NR and NMN are related B3 derivatives but haven't shown the same lipid-lowering profile in trials.
Will taking an NAD+ supplement raise my cholesterol?
The safety data available (an 8-week NR trial) found no LDL increase. That's reassuring for safety, though it's a different question from whether it lowers cholesterol.
Should I take NAD+ Restore instead of my statin?
No — this isn't a treatment for high cholesterol, and no trial has tested it as a replacement or add-on to statin therapy. Talk to your doctor about managing diagnosed high cholesterol.
Cholesterol and blood pressure changes often show up together in the same trials, since both are markers of broader cardiometabolic health — see our companion article on NAD+ and blood pressure for the related vascular evidence, and our deeper dive into the NAD+, resveratrol, and CoQ10 stack evidence for how these compounds are often combined in practice.
Does the polyphenol pairing (resveratrol, quercetin) affect cholesterol separately?
These compounds have their own, separate research literature on lipid metabolism, but the trials discussed here tested NAD+ precursors specifically. There isn't strong combination-specific data confirming an added cholesterol benefit from pairing them.
It’s worth separating this from niacin’s well-known cholesterol effects specifically, since the two get conflated often. Niacin (nicotinic acid) lowers LDL and raises HDL at prescription-level doses (typically 1,000–2,000 mg/day), but causes a well-documented flushing reaction and requires liver-enzyme monitoring at those doses. NR and NMN are metabolized through a different route that avoids the flushing reaction, and the 8-week NIAGEN safety trial specifically found NR did not elevate LDL cholesterol — a reassuring safety finding, but a different question from whether it actively lowers cholesterol the way therapeutic niacin does. That distinction is worth keeping straight: "doesn’t raise LDL" and "lowers LDL" are not the same claim, and only the second is what most people are hoping for when they ask about cholesterol.
From Nuvirox
Why we formulated NAD+ Restore
If what you're dealing with sounds like it belongs in a doctor's office rather than a supplement aisle, please start there — a clinician can rule out the specific causes discussed above. For general cellular energy support, each serving of NAD+ Restore provides 500 mg of nicotinamide riboside chloride (NR), one of the two most-researched NAD+ precursors, within the dose range used in published human trials, alongside 150 mg trans-resveratrol and 50 mg quercetin (polyphenols studied alongside NAD+ pathways for cellular health support) and 10 mg of galactomannans from fenugreek to support absorption.
We back it with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
If you're hoping NAD+ precursors will meaningfully move your cholesterol numbers, the most rigorous evidence available — a meta-analysis of 8 randomized trials — doesn't support that expectation on average. One smaller trial in overweight adults found a real LDL drop, which is worth watching as more research comes in, but it's a single result, not a pattern. The fair reading right now is 'unproven, plausible, worth monitoring' rather than 'effective.'
References
- Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Curr Diab Rep. 2024. doi:10.1007/s11892-024-01557-z. PMCID: PMC11557618.
- Pencina KM, Valderrabano R, Wipper B, et al. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. J Clin Endocrinol Metab. 2023;108(8):1968-1980. doi:10.1210/clinem/dgad027.
- Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep. 2019;9:9772. doi:10.1038/s41598-019-46120-z.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.